Costing and availability of drug therapy and diagnostic assays for cryptococcal infection
This presentation is the property of its rightful owner.
Sponsored Links
1 / 13

COSTING AND AVAILABILITY OF DRUG THERAPY AND DIAGNOSTIC ASSAYS FOR CRYPTOCOCCAL INFECTION PowerPoint PPT Presentation


  • 89 Views
  • Uploaded on
  • Presentation posted in: General

COSTING AND AVAILABILITY OF DRUG THERAPY AND DIAGNOSTIC ASSAYS FOR CRYPTOCOCCAL INFECTION. Iman Wanis , Cushla Coffey, Shaffiq Essajee , and Philippa Easterbrook World Health Organization, HIV Department (ATC) Geneva, Switzerland July 2011. CRYPTOCOCCAL DRUGS AND DIAGNOSTICS.

Download Presentation

COSTING AND AVAILABILITY OF DRUG THERAPY AND DIAGNOSTIC ASSAYS FOR CRYPTOCOCCAL INFECTION

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Costing and availability of drug therapy and diagnostic assays for cryptococcal infection

COSTING AND AVAILABILITY OF DRUG THERAPY AND DIAGNOSTIC ASSAYS FOR CRYPTOCOCCAL INFECTION

ImanWanis, Cushla Coffey, ShaffiqEssajee,

and Philippa Easterbrook

World Health Organization, HIV Department (ATC)

Geneva, Switzerland

July 2011


Cryptococcal drugs and diagnostics

CRYPTOCOCCAL DRUGS AND DIAGNOSTICS


Funding and supply distributors for drugs

Funding and Supply/Distributors for Drugs

  • UNITAID/CHAI

  • The Global Fund

  • PEPFAR

  • National Government

  • NGOs e.g. MSF

  • Self-pay


Challenges in the use of supplied medicines

Challenges in the use of supplied medicines

  • Orders were low

  • Stock went unused

  • Countries had difficulty predicting need

  • Countries were not able to track cases or monitor use

  • Lack of consistent country practice and the need for clear guidance


Costing and availability of drug therapy and diagnostic assays for cryptococcal infection

UNITAID/CHAI

Progress of the projects

Performance of suppliers

Achievement of key objectives

* Source: A meeting with UNITAID/CHAI Pediatrics ARVs Project Coordinator


Programmatic experience in unitaid chai pediatric amphotericin donation programme

Programmatic Experience in UNITAID/CHAI Pediatric Amphotericin Donation Programme

  • Underutilised, orders were low

  • Clinicians not well informed about programme (reports of unused or expiring stock in pharmacy)

  • Not clear whether drugs are used for children or adults

  • No standardisation of process e.g.

    • Tracking and monitoring of use

    • Liaison with clinics

    • Forecasting/product quantifications

  • Need for consistent country practice and guidance


Data sources for drug costs

Data Sources for Drug Costs

1. International Drug Price Indicator Guide (IDPI)

  • Published by Management Sciences for Health (MSH) since 1986

  • Annually updated

  • Prices from pharmaceutical suppliers, international development organizations, and government agencies

    2. Global Price Reporting Mechanism (GPRM) http://www.who.int/hiv/amds/gprm/en/

  • Web-based database launched by the AMDS in April 2005

  • Reports of price quotes from pharmaceutical companies, and other sources.

  • Price monitoring tool

  • Prices of drugs purchased and supplied by various procuring agencies for different countries: CHAI, Mission Pharma, MSH, PFSCMS, UNDP, UNFPA, UNICEF, UNITAID

    4. Telephone Country Survey: 8 HIV clinicians, 1 laboratory director, 1 clinical microbiologist, 1 pharmacist, NAP director and 1 Information Management advisor.


Amphotericin b ampho fluconazole fluc costs in sub saharan africa gprm

Amphotericin B (ampho) + Fluconazole (fluc) Costs in Sub Saharan Africa (GPRM)

Uganda (2009) $2.6/50mg ampho

$0.7/200mg fluc

Burundi (2009) $2.6/50mg ampho

$0.07/200mg fluc

Angola (2008) $12.31/50mg ampho

$0.174/200mg fluc

Malawi (2009) $2.48/50mg ampho

$0.07/200mg fluc


Costing and availability of drug therapy and diagnostic assays for cryptococcal infection

Comparison of Costs of Amphotericin B and Fluconazole in IDPI (2010) & GPRM (2006-2010) Databases & Field Data


Flucytosine cost estimates from world wide web resources

Flucytosine Cost estimates from World Wide Web resources


Diagnostics cost estimates from the field

Diagnostics Cost Estimates from the field

LA= CRAG Latex Agglutination LFA= CRAG Lateral Flow Assay SCMS= Supply Chain Management System


Cost estimates from literature

Cost estimates from Literature


Data limitations

Data Limitations

  • GPRM

    • Data ranges from 2004 – 2010, so comparisons between countries difficult

    • Data from only a few manufacturers.

  • Comparisons between IDPI, GPRM unreliable because:

    • Multiple sources of data from manufacturers (GPRM), suppliers and buyers

    • Data from different years.


  • Login